ABSTRACT: A new series of N'-((1-(substituted amino)methyl)-2-oxoindolin-3-ylidene)-4-(2-(methyl/ phenyl)-4-oxoquinazolin-3(4H)-yl)benzohydrazide derivatives 4a-4l were designed and synthesized from anthranilic acid. All the synthesized compounds were characterized by spectroscopic means and elemental analyses. The tail-flick technique and the carrageenaninduced foot paw edema test were performed for screening analgesic and anti-inflammatory activity, respectively. All of the compounds were also examined for their ulcerogenicity. Some of the compounds showed significant activity. Among the test compounds, 4b exhibited 53% and 69% analgesic activity at a dose of 10 and 20 mg/kg, respectively. It also displayed 47% (10 mg/kg) and 65% (20 mg/kg) anti-inflammatory activity with one-fourth of ulcer index of the reference drugs diclofenac and aspirin.
Introduction
Inflammation is a defensive but exaggerated local tissue reaction in response to exogenous or endogenous insult. It is a fundamental physiological process that is not only essential for survival but at the same time is one of the major causes of human morbidity and mortality (1, 2) . A large number of non-steroidal anti-inflammatory drugs (NSAIDs) are available clinically to treat inflammatory disorders. NSAIDs are one of the most widely used drug categories against inflammation, mild to moderate pain and fever. In the past decade, numerous advances have taken place in the understanding of pathogenesis and as a result, significant progress has been made and is still being explored for the development of novel NSAIDs (3). Prostaglandin synthetase or cyclooxygenase (COX) is an enzyme which catalyzes the rate limiting steps in the biosynthesis of cyclic endoperoxides from arachidonic acid to form prostaglandins (PGs). The most important mechanism of NSAIDs is considered to be primarily by inhibition of PGs synthesis; specifically competitive inhibition of COX (4) . Generally, the NSAIDs inhibit both isoforms COX-1 and COX-2. Most NSAIDs are mainly COX-1 selective (e.g., indomethacin, aspirin, ketoprofen, piroxicam, and sulindac). The mechanism of action of celecoxib and rofecoxib is primarily selective inhibition of COX-2 (5) . Others are considered to have mixed action on COX-1 and -2 (e.g., ibuprofen, naproxen, diclofenac, etodolac, nabumetone, and meloxicam). Other mechanisms that may contribute to NSAID mediated anti-inflammatory activity include the reduction of superoxide radicals, induction of apoptosis, inhibition of adhesion molecule expression, decrease of nitric oxide synthase, decrease of proinflammatory cytokine levels (tumornecrosis factor-α, interleukin-1), modification of lymphocyte activity, and alteration of cellular membrane functions (6) . However, long term clinical usages of NSAIDs are associated with significant side effects such as severe gastrointestinal ulceration, bleeding, intolerance and nephrotoxicity (7, 8) . Therefore, investigation of new NSAIDs is still a major challenge and production of safer and more active NSAIDs and analgesic drugs are needed.
Quinazoline and quinazolinone nuclei have drawn great attention due to their wide range of chemotherapeutic activities (9) (10) (11) (12) (13) (14) (15) . Additionally, different known anti-inflammatory drugs such as proquazone I, fluoroquazone II, and tryptanthrin III contain the quinazoline nucleus (Figure 1) (16-19) reported that the substitution pattern by different aryl or heteroaryl moieties at 2/3 position of the quinazoline nucleus markedly influences analgesic and antiinflammatory activity (20) .
On the other hand the indole skeleton exists in a variety of natural products and is the precursor for many pharmaceuticals, such as indomethacin IV, etodolac V, and tenidap VI (Figure 1 ). In recent decades, the literature has been enriched with progressive findings about synthesis and pharmacological activities of isatin (oxidized form of indole) ring, which is a core structure in various synthetic pharmaceuticals displaying a wide variety of biological activities (21) (22) (23) (24) (25) (26) (27) .
Based on the above observations and in continuation of our anti-inflammatory and analgesic drug research program (28, 29) , it was of interest to synthesize a novel series of quinazolinone derivatives with structure modifications involving incorporation of isatin moieties at the 3rd position and a methyl/phenyl group at the 2nd position of the quinazolinone ring as a trial to obtain safer and potent anti-inflammatory and analgesic agents. The ulcerogenic activity of the compounds was also determined.
Materials and Methods

Chemistry
The chemicals and reagents used were obtained from various chemical units Merck India Ltd., Qualigens, CDH, and SD Fine Chem. All solvents used were of laboratory research (LR) grade and purified before use.
All reaction steps were monitored until completion using thin layer chromatography (TLC). An iodine chamber and UV lamp were used for visualization of TLC spots. All melting points were performed in open glass capillary tubes and were uncorrected. 1 H-NMR spectra were performed on a Bruker ultra shield (300 MHz) NMR spectrometer in CDCl 3 using tetramethylsilane [(CH 3 ) 4 Si] as an internal standard. Chemical shifts (δ) were expressed as parts per million (ppm). The multiplicities of the signals in the 1 H-NMR spectra were abbreviated by s (singlet), t (triplet), q (quartet), and m (multiplet). The J constant was given in Hz. Mass spectra were obtained on a JEOL-SX-102 instrument using electron impact ionization. All IR spectra were recorded in KBr pellets on a Jasco FT-IR 410 spectrometer. Elemental analyses were performed on a PerkinElmer model 240C analyzer and were within ± 0.4% of the theoretical values.
For the synthesis of the 2-methyl derivative: A mixture of anthranilic acid (1.37 g, 0.01 mol) and acetic anhydride (10.2 mL, 0.1 mol) was refluxed on a gentle flame for 1 h. The excess acetic anhydride was distilled off under reduced pressure and the residue was dissolved in petroleum ether and was kept aside for 1 h. The light brown solid 1a obtained was filtered and dried (28) .
For synthesis of the 2-phenyl derivative: To a solution of anthranilic acid 13.7 g (0.1 mol) dissolved in pyridine (60 mL), benzoyl chloride 28 g (0.2 mol) was added and the mixture was stirred for 30 min at room temperature followed by treatment with 5% NaHCO 3 (15 mL). The solid thus obtained 1b was recrystallized from ethanol (29).
Synthesis of 4-(2-(methyl/phenyl)-4-oxoquinazolin-3(4H)-yl)benzohydrazide (2a, 2b)
A mixture of 2-(methyl/phenyl)-4H-benzo [1, 3] oxazin-4-one 1a/1b (1.61/2.23 g, 0.01 mol) and p-aminobenzohydrazide (1.51 g, 0.01 mol) was dissolved in anhydrous pyridine (50 mL) and heated on a sand bath for 10 h. The resulting solution was cooled in an ice bath and treated with dilute hydrochloric acid (100 mL). The product separated 2a/2b was filtered, washed with water, and crystallized from ethanol. 
Anti-inflammatory activity
Anti-inflammatory activity was evaluated by the carrageenan-induced paw edema test in rats (33) . Diclofenac sodium at 10 and 20 mg/kg was administered as a reference drug for comparison. The test compounds were administered at two dose levels (10 and 20 mg/kg). The paw volumes were measured using the mercury displacement technique with the help of a plethysmograph immediately before and 30 min, 1, 2, and 3 h after carrageenan injection. The percent inhibition of paw edema was calculated according to the following formula: percent inhibition I = 100 × [1 -(ax)/(b -y)] where x is the mean paw volume of rats before the administration of carrageenan and the test compounds or the reference drug (test group), a is the mean paw volume of rats after the administration of carrageenan in the test group (drug treated), b is the mean paw volume of rats after the administration of carrageenan in the control group, y is the mean paw volume of rats before the administration of carrageenan in the control group.
Ulcerogenicity
Ulceration in rats was induced as reported by Goyal et al. (34) . Albino Wistar rats weighing 150-200 g of either sex were divided into various groups of six animals each. The control group of animals was only given 10% (v/v) Tween-80 suspension intraperitoneally. One group was administered with aspirin intraperitoneally at a dose of 200 mg/kg once daily for three days. Diclofenac was also administered as a standard drug at 20 mg/kg once daily for three days to another group of animals by the same route. The remaining group of animals was given the test compounds intraperitoneally at a dose of 20 mg/kg. On the fourth day, the pylorus was ligated using the method of Shay et al. (35) . Animals were fasted for 36 h before the pylorus ligation procedure. The animals were sacrificed four hours post ligation. The stomach was removed and opened along with the greater curvature. Ulcer index was determined by the method of Ganguly and Bhatnagar (36).
Results and Discussion
Chemistry
The synthetic pathway giving access to the titled compounds 4a-4l is represented in Scheme 1. Initially, 2-(methyl/phenyl)-4H-benzo [1, 3] oxazina steam bath for 1 h. After standing for approximately 24 h at room temperature, the crystalline products 3a/3b were separated by filtration, dried under vacuum pressure and recrystallised from ethanol.
General procedure for the synthesis of N'-((1-(substituted amino)methyl)-2-oxoindolin-3-ylidene)-4-(2-(methyl/phenyl)-4-oxoquinazolin-3(4H)-yl)benzohydrazide (4a-4l)
To a solution of the derivative 3a/3b (4.23/4.85 g, 0.01 mol) in glacial acetic acid (50 mL) containing 37% formalin (1 mL), the appropriate secondary amine derivative (0.02 mol) was added. The reaction mixture was refluxed on a water bath for 1-3 h. The reaction mixture was concentrated to approximately half the initial volume, and the resulting precipitate was recrystallized from ethanol to get a pure form of the product. The method used for the preparation and isolation of the compounds gave materials of good purity, as evidenced by their spectral analyses and by TLC. The spectral data for the title compounds 4a-4l are presented in the appendix.
Animals
The animals used in the present study were Swiss albino mice weighing 20-25 g and Wistar rats weighing 150-200 g were procured from Bapatla College of Pharmacy, Bapatla, India. Animals were maintained in colony cages at 25 ± 2°C, relative humidity of 45-55%, maintained under 12 h light and dark cycle and were fed standard animal feed (30) and water ad libitum. Animals were maintained under standard conditions in an animal house approved by the committee for the purpose of control and supervision on experiments on animals (CPCSEA). The protocol was approved by the Institutional Animal Ethics Committee. All animals were acclimatized to laboratory conditions for a week before use.
The synthesized compounds were evaluated for analgesic, anti-inflammatory and ulcerogenic activities. One-way analysis of variance (ANOVA) was performed to obtain significance for all exhibited activities. Test compounds and standard drugs were administered in the form of a suspension (1% carboxy methyl cellulose as a vehicle) by the oral route for analgesic and antiinflammatory studies and as a suspension of 10% (v/v) Tween-80 by the intraperitoneal route of administration for ulcerogenicity studies.
Analgesic activity
The analgesic activity was performed by the tail-flick technique using Wistar albino mice (25-35 g ) of either sex selected by a random sampling technique (31, 32) . Diclofenac sodium at a dose level of 10 and 20 mg/kg was administered orally as a reference drug for comparison. The test compounds at two dose levels (10 and 20 mg/kg) were 4-one 1a/1b were synthesized from anthranilic acid using acetic anhydride/benzoyl chloride by a simple acetylation/benzoylation followed by a ring closure reaction. In the subsequent step, 4-(2-(methyl/phenyl)-4-oxoquinazolin-3(4H)-yl)benzohydrazide 2a/2b were synthesized by a simple reaction of compounds 1a/1b with p-aminobenzohydrazide with elimination of a water molecule. Before the final step, Schiff bases 3a/3b were synthesized by nucleophilic addition of the amino derivatives 2a/2b with the carbonyl compound isatin in ethanol. This reaction was followed by dehydration to generate compounds 3a/3b by forming a stable imine. In the last step, the title compounds 4a-4l were synthesized through a Mannich reaction by treating compound 3a/3b with formaldehyde and secondary amines like dimethylamine, diethylamine, diphenylamine, piperazine, morpholine, and piperidine. The physicochemical parameters of all the synthesized compounds are summarized in Table 1 . The structures of the synthesized compounds were confirmed by spectral (IR,   1 H-NMR, and Mass) and elemental analyses data.
Using Wistar albino mice analgesic activity for title compounds 4a-4l was carried out by the tail-flick technique. The results obtained from the above study are summarized in Table 2 . The results of analgesic activity indicate that all the test compounds exhibited a graded dose response and not all of them are significant but some of them gave significant activity. Moreover, this study revealed that test compounds showed moderate 81 analgesic activity at 30 min of reaction time; the activity increased at 1 h, further it reached to peak level at 2 h and it decreased again at 3 h. Compound 4a and 4g with dimethyl substitution showed good activity. With the increased lipophilicity (diethyl group), compounds 4b and 4h showed an increase in activity. Substitution with alicyclic amine (piperidine) in 4f and 4l further increases the lipophilicity and retains the activity of diethyl substitution. The presence of an additional hetero atom such as nitrogen and oxygen in the alicyclic amine rings such as: (piperazine and morpholine) in 4d, 4e, 4j, and 4k led to a decrease in activity which might be due to a fall in lipophilicity. Aromatic substitution (diphenyl group) in 4c and 4i showed lower activity. The compounds with aliphatic substitution 4a, 4b, 4g, and 4h had shown better activity than the rest of the compounds 4c-4f and 4i-4l with alicyclic amine or aromatic substitution. Compounds 4b, 4f, 4h, and 4l were found to be the most active analgesic agents and they are almost equal or moderately more potent when compared to the reference standard diclofenac sodium.
Anti-inflammatory activity
Anti-inflammatory activity was performed by the carrageenan-induced paw edema test in rats. The antiinflammatory activity results (Table 3) showed that all test compounds protected rats from carrageenan-induced inflammation reasonably at 30 min of reaction time; the activity increased at 1 h and it reached the maximum level at 2 h. Declining activity was observed at 3 h. The compounds possessing dimethyl amino substituents 4a Each value represents the mean ± SEM (n = 6). Significance levels * p < 0.5, ** p < 0.01, *** p < 0.001 as compared with the respective control.
and 4g exhibited equipotent anti-inflammatory activity to the reference standard diclofenac sodium. With increased lipophilicity, compounds with diethyl amino substituents 4b and 4h showed moderately more potent activity than that of diclofenac sodium. Unlike analgesic activity, the replacement of these alkyl groups with the alicyclic amine (piperidine) in 4f and 4l led to a sharp decrease in activity. Placement of an additional hetero atom such as nitrogen and oxygen with the alicyclic amine (piperazine and morpholine) in 4d, 4e, 4j, and 4k showed a further decrease in activity. Among all the synthesized compounds, 4c and 4i with aromatic substitution (diphenyl amino group) exhibited the least activity. Moreover among the tested compounds, 2-methyl quinazolinone derivatives showed greater analgesic and anti-inflammatory activity than the corresponding 2-phenyl quinazolinone analogs.
Ulcerogenicity
In addition all test compounds were examined for ulcerogenicity and the results are summarized in Table  3 . All test compounds exhibited ulcer indexes less than those obtained with the standard diclofenac and aspirin.
Results of the ulcer index revealed that compounds bearing alkyl substituents 4a, 4b, 4g, and 4h showed a negligible ulcer index, whereas the replacement of the methyl group with a phenyl group at the 2nd position of the quinazoline ring led to a slight increase in the ulcer index. The other test compounds, 4d-4f and 4j-4l possessing alicyclic amines exhibited a higher ulcer index. The test compounds exhibited 29-57% and 26-51% of the ulcer index when compared to the reference drug diclofenac (1.61 ± 0.53) and aspirin (1.79 ± 0.65), respectively. Among the tested compounds, N'- Each value represents the mean ± SEM (n = 6). Significance levels * p < 0.5, ** p < 0.01, *** p < 0.001 as compared with the respective control. by IR, 1 H-NMR, mass spectroscopy and elemental analyses. Some of the test compounds exhibited significant analgesic and anti-inflammatory activity with a mild to moderate ulcer index. In general, it was found that 2-methyl quinazolinone analogs showed more potent activity than corresponding 2-phenyl quinazolinone derivatives. Also, quinazoline derivatives bearing alkyl amino groups exhibited the best activity followed by derivatives bearing alicyclic amines whereas derivatives having aryl amino groups showed the least activity. Among all test compounds, N'-(1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-4-(2-methyl-4-oxoquinazolin-3(4H)-yl)benzohydrazide 4b showed the most potent analgesic and anti-inflammatory activity which is more potent than that of the reference diclofenac. From this study we concluded that incorporation of an isatin moiety at the 3rd position and a methyl group at the 2nd position of the quinazolinone ring resulted in potent analgesic and anti-inflammatory activity with a minimal ulcer index. Hence, this analog could be developed as a new class of analgesic and anti-inflammatory agents. However, further structural modification should be planned to enhance their analgesic and anti-inflammatory activities with the low ulcerogenic index.
Characterization data of the synthesized compounds in the current study 2-Methyl-4H-benzo [1, 3] 
4-(2-Methyl-4-oxoquinazolin-3(4H)-yl)-N'-(2-oxoindolin-3-ylidene)benzohydrazide (3a
4-(4-Oxo-2-phenylquinazolin-3(4H)-yl)-N'-(2-oxoindolin-3-ylidene)benzohydrazide (3b
N'-(1-((dimethylamino)methyl)-2-oxoindolin-3-ylidene)-4-(2-methyl-4-oxoquinazolin-3(4H)-yl)benzohydrazide (4a
N'-(1-((diphenylamino)methyl)-2-oxoindolin-3-ylidene)-4-(2-methyl-4-oxoquinazolin-3(4H)-yl)benzohydrazide (4c
